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SOME EVIDENCES ABOUT
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HEMORRHAGIC FEVER
 
Ali Jabbari1, Sima Besharat2, Abdollah Abbasi3 
This refers toDr. Levent Doganci’s letter 
published in your valuable Journal about 
Congo Hemorrhagic Fever (CCHF) entitled 
“Crimean Congo Haemorrhagic Fever as an 
indication for use of Ribavirin”.1 Crimean-
Congo Hemorrhagic Fever is a widely distrib­
uted lethal disease, worldwide.2 Human are 
usually infected with CCHF virus through a 
tick bite or close contact with viral contami­
nated tissues or with blood of domestic ani­
mals or of infected patients.2-4 There are a few 
clinical and epidemiologically re-emerging 
points, which need to be highlighted about this 
deadly viral infection. 
We reported a case-series about patients who 
suffered from CCHF in northeast of Iran (2004­
2006). We saw a good clinical response to in­
travenous prescription or oral form of Ribavirin 
at the early stages of the disease along with 
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high dose corticosteroids, intensive monitoring, 
careful attention to fluid balance, correction of 
electrolyte abnormalities, appropriate treat­
ment of secondary infections, enough oxygen­
ation, massive transfusion and hemodynamic 
support; depending upon the situation.4 
Human cases of Crimean Congo Hemor­
rhagic Fever (CCHF) have been reported from 
Turkey, since 2002 with increasing morbidity 
rate and some fatalities. CCHF can be consid­
ered as an endemic lethal disease in that 
region.5,6 
Based on our clinical experience, Ribavirin 
could be considered as a useful medicine for 
CCHF therapy in endemic regions but in the 
early stages of clinical process. Ribavirin was 
also recommended in post-exposure prophy­
laxis to soldiers in Operation Desert Shield/ 
Storm and in Korea.7 Clinical features usually 
include a rapid progression characterized by 
hemorrhage, myalgia and fever, with 30% 
mortality rate and it can develop up to 50%.8 
According to the clinical response and cure 
seen in most of the patients who were treated 
with antiviral agents such as Ribavirin accom­
panied with corticosteroids, intensive monitor­
ing and conservative therapy, it can be con­
cluded that this treatment can be considered 
as a good treatment protocol, if prescribed at 
the early stages. Delay in diagnosis decreases 
the efficacy of treatment and aggravates the 
outcome of the disease. 
This important fact that “early ribavirin use 
in the beginning of illness has significant posi­
tive effect on survival” has also been empha­
sized in other reports.9-11 In addition, Ribavirin 
is a WHO recommended anti-viral for CCHF. 
Thus, we suggest this method of treatment as 
a basic treatment protocol in the early stages 
of CCHF.4 
It should also be noted that one of the most 
prominent differences between Iran and 
Turkey and some other countries is the route 
of virus transmission. As Dr. Doganci pointed 
out in the manuscript, tick exposure and tick 
removal can be the main life saving protocol, 
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while the major root of transmission is the tick 
bite. It is confirmed that one of the major roots 
of transmission is the tick bite2,3; but some other 
reports showed that close contact with sheep 
had the main role in the transmission.12 It 
should be kept in mind that in some special 
areas, like Northeast of Iran and Turkey, which 
sheepherding is one of the most common jobs, 
the route of contamination could be different. 
Therefore, CCHF must be considered as a job 
hazardous. Sheep, goats and cattle develop 
high titers of virus in blood, but tend not to fall 
ill. People who work with livestock, animal 
herders and slaughterhouses workers, in en­
demic areas like Iran and Turkey are at risk of 
CCHF and must take measures for protection. 
Medical laboratory staffs are another high-risk 
group. Diagnosis of CCHF is important to pre­
vent the spread of CCHF virus among the 
health-care workers and relatives of patients. 
Protection of tick exposure and appropriate tick 
removal has a life saving potency. 
We fully support the valuable advice of the 
author, and suggest that in low–income af­
fected population who come from the farms 
of rural areas, CCHF can be added as an indi­
cation of Ribavirin to solve this life–threaten­
ing problem. In the endemic areas, ecological 
changes, poverty, social instability, insufficient 
medical equipment, and absence of standard 
infection control practices have contributed to 
increase transmission of virus.8 So; CCHF is a 
disease with several predisposing factors, and 
its outbreak constitute a threat to public health 
services because of increased transmission in 
its natural environment, in the community, 
and in the hospital settings. 
A practical advice for protection can be as 
following: use insect repellent on exposed skin 
besides wearing gloves and other protective 
cloths. Insect repellants containing DEET (N, 
N-diethyl-m-toluamide) are the most effective 
in warding off ticks.13 Individuals should also 
avoid contact with the blood and body fluids 
of livestock or human who show symptoms of 
infection.13 
An inactivated, mouse-brain derived vaccine 
against CCHF has been developed and is used 
on a small scale in Eastern Europe. However, 
there is no safe and effective vaccine widely 
available for human use.13 Immune plasma has 
been used to treat CCHF patients, but its 
effects have not been studied with controls. 
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